Effect of weight-adjusted intermediate-dose versus fixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism among …
S Zuily, B Lefèvre, O Sanchez, OE de Vendin… - …, 2023 - thelancet.com
Background Venous thromboembolism is a major complication of coronavirus disease 2019
(COVID-19). We hypothesized that a weight-adjusted intermediate dose of anticoagulation …
(COVID-19). We hypothesized that a weight-adjusted intermediate dose of anticoagulation …
Therapeutic-dose anticoagulation or thromboprophylaxis with low-molecular-weight heparin for moderate COVID-19: Meta-analysis of randomized controlled trials
J Ena, V Valls - Clinical and Experimental Medicine, 2023 - Springer
Background We carried out a meta-analysis since there is not enough evidence to
recommend for or against therapeutic-dose anticoagulation compared with …
recommend for or against therapeutic-dose anticoagulation compared with …
[HTML][HTML] Thromboprophylaxis in COVID‐19: weight and severity adjusted intensified dosing
MM Engelen, C Vandenbriele, V Spalart… - Research and Practice …, 2022 - Elsevier
Background Venous thromboembolism (VTE) frequently occurs in hospitalized patients with
coronavirus disease 2019 (COVID‐19). The optimal dose of anticoagulation for …
coronavirus disease 2019 (COVID‐19). The optimal dose of anticoagulation for …
Efficacy and safety of two heparin regimens for prevention of venous thromboembolism in hospitalized patients with COVID-19: a meta-analysis
MC Vedovati, M Graziani, G Agnelli… - Internal and Emergency …, 2023 - Springer
Venous thromboembolism (VTE) is common in patients with coronavirus disease-2019
(COVID-19). The optimal heparin regimen remains unknown and should balance …
(COVID-19). The optimal heparin regimen remains unknown and should balance …
[HTML][HTML] Therapeutic anticoagulation to prevent thrombosis, coagulopathy, and mortality in severe COVID‐19: The Swiss COVID‐HEP randomized clinical trial
M Blondon, S Cereghetti, J Pugin, C Marti… - Research and Practice …, 2022 - Elsevier
Background Hospitalized patients with COVID‐19 suffered initially from high rates of venous
thromboembolism (VTE), with possible associations between therapeutic anticoagulation …
thromboembolism (VTE), with possible associations between therapeutic anticoagulation …
The Impact of Risk-Adjusted Heparin Regimens on the Outcome of Patients with COVID-19 Infection. A Prospective Cohort Study
Background. According to recent guidelines, all hospitalized patients with COVID-19 should
receive pharmacological prophylaxis for venous thromboembolism (VTE), unless there are …
receive pharmacological prophylaxis for venous thromboembolism (VTE), unless there are …
Use of low-molecular weight heparin, transfusion and mortality in COVID-19 patients not requiring ventilation
E Grandone, G Tiscia, R Pesavento… - Journal of Thrombosis …, 2021 - Springer
It is still debated whether prophylactic doses of low-molecular-weight heparin (LMWH) are
always effective in preventing Venous Thromboembolism (VTE) and mortality in COVID-19 …
always effective in preventing Venous Thromboembolism (VTE) and mortality in COVID-19 …
High-dose versus low-dose venous thromboprophylaxis in hospitalized patients with COVID-19: a systematic review and meta-analysis
E Valeriani, A Porfidia, W Ageno, S Spoto… - Internal and emergency …, 2022 - Springer
Background Hospitalized COVID-19 patients are at high risk of venous thromboembolism
(VTE). Standard doses of anticoagulant prophylaxis may not be sufficiently effective for the …
(VTE). Standard doses of anticoagulant prophylaxis may not be sufficiently effective for the …
Standard-versus intermediate-dose enoxaparin for anti-factor Xa guided thromboprophylaxis in critically ill patients with COVID-19
DO Hamilton, A Main-Ian, J Tebbutt, M Thrasher… - Thrombosis …, 2021 - Springer
The prevalence of venous thromboembolism (VTE) is high in critically ill patients with COVID-
19. Dosing of Low Molecular Weight Heparin (LMWH) for thromboprophylaxis in patients …
19. Dosing of Low Molecular Weight Heparin (LMWH) for thromboprophylaxis in patients …
Enoxaparin for thromboprophylaxis in hospitalized COVID‐19 patients: the X‐COVID‐19 randomized trial
N Morici, GM Podda, S Birocchi… - European journal of …, 2022 - Wiley Online Library
Background It is uncertain whether higher doses of anticoagulants than recommended for
thromboprophylaxis are necessary in COVID‐19 patients hospitalized in general wards …
thromboprophylaxis are necessary in COVID‐19 patients hospitalized in general wards …